Ken Griffin Seres Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$0.75 - $1.56 $27,825 - $57,876	-37,100 Reduced 50.14%	36,900 $28,000
Q4 2023 Feb 14, 2024	BUY	$0.93 - $2.15 $5,673 - $13,115	6,100 Added 8.98%	74,000 $103,000
Q3 2023 Nov 14, 2023	SELL	$2.33 - $5.07 $165,896 - $360,984	-71,200 Reduced 51.19%	67,900 $161,000
Q2 2023 Aug 14, 2023	BUY	$4.67 - $6.55 $340,443 - $477,495	72,900 Added 110.12%	139,100 $666,000
Q1 2023 May 15, 2023	BUY	$4.95 - $6.09 $27,225 - $33,495	5,500 Added 9.06%	66,200 $375,000

Q4 2022 Feb 14, 2023	SELL	$5.09 - $9.05 $19,851 - $35,295	-3,900 Reduced 6.04%	60,700 $339,000
Q3 2022 Nov 14, 2022	BUY	$3.5 - $7.2 $134,750 - $277,200	38,500 Added 147.51%	64,600 $415,000

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.